Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Study Identifies Inherited Pathogenic Germline Variants in Pediatric Neuroblastoma

TON - June 2021 Vol 14, No 3 - AACR Highlights

Researchers have identified 2 inherited pathogenic genetic variants in patients with pediatric neuroblastoma, according to results from a study presented at the 2021 virtual American Association for Cancer Research annual meeting. Both variants—the ALK gene and loss of function in PHOX2B—are associated with worse outcomes.

“The observed association of pathogenic/likely pathogenic germline variants with worse outcomes suggests that we need a more thorough evaluation of patients with neuroblastoma than is currently performed as standard of care,” said Emily Blauel-Bocko, MD, Attending Physician, Children’s Hospital of Philadelphia, PA, and lead investigator of the study.

“This study is very important. It opens the door to genetic counseling for these families and the possibility of preventing some of these cases,” she continued.

Neuroblastoma is a pediatric cancer that arises from the sympathetic nervous system. It accounts for 8% of pediatric cancers and 12% to 15% of pediatric cancer mortality.

“Neuroblastoma is characterized by highly diverse clinical behavior—from spontaneous regression to relentless progression,” Dr Blauel-Bocko explained. “Only 1% to 2% have a family history of disease, ie, familial neuroblastoma. The remainder are thought to arise spontaneously [sporadic].”

Although recent studies estimate that approximately 8% to 10% of pediatric patients spanning all cancer types harbor a rare pathogenic or likely pathogenic germline variant in a cancer predisposition gene, the heritability of such germline variants remains largely unknown because of limited parental data.

Study Details

The research was conducted with the support of the Gabriella Miller Kids First Pediatric Research Program. Dr Blauel-Bocko and colleagues studied paired samples from children and parents using whole-genome sequencing of germline DNA from 556 patients with neuroblastoma and 1 or both of their biologic parents (457 samples from patients and both parents and 99 patients with 1 biologic parent).

The researchers sampled tumor DNA in 336 samples and tumor RNA in 207 samples. They found 93 pathogenic/likely pathogenic variants in known cancer predisposition genes in 90 patients, or 16% of the cohort.

Two main pathogenic/likely pathogenic genes were identified: ALK, which accounts for 75% to 80% of neuroblastoma, and loss of function in PHOX2B, accounting for 5% to 10% of neuroblastoma.

Compared with controls, enrichments in genes associated with repair defects were observed in patients with identified pathogenic/likely pathogenic variants. In addition, 95% of the identified germline variants were inherited, with a distribution of 54% maternal and 46% paternal inherited patterns (6% were de novo).

Importantly, the presence of these germline variants correlated with worse event-free survival (P = .0107) and worse overall survival (P = .0015).

“The association between pathogenic/likely pathogenic germline variants and high-risk and high-stage trended toward significance,” Dr Blauel-Bocko noted.

Further research will analyze host–tumor interactions and modifying factors of disease. One important focus is to understand the genotype and phenotype relationship in children who have neuroblastoma and parents who never developed it despite the presence of genetic alterations.

Related Items
Practice-Changing Results Observed with Adjuvant Pembrolizumab Therapy for Renal-Cell Carcinoma
Patricia Stewart
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Renal-Cell Carcinoma
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Patricia Stewart
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Breast Cancer
Targeted Radiotherapy Extends Survival for Patients with Advanced Prostate Cancer
Patricia Stewart
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Prostate Cancer
Sotorasib Shows Promising Activity in Patients with NSCLC and KRAS Mutation
Patricia Stewart
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Lung Cancer
Addition of Copanlisib to Rituximab Improves Outcomes in Indolent NHL
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in AACR Highlights
Selpercatinib Demonstrates Encouraging Activity in a Range of RET Fusion–Positive Solid Tumors
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in AACR Highlights
Becoming Pregnant Is Feasible But Less Likely for Breast Cancer Survivors
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Survivorship
Current and Future Effects of the COVID-19 Pandemic on Cancer Care
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in COVID-19
Enfortumab Vedotin Prolongs Survival in Patients with Metastatic Urothelial Cancer
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Urothelial Cancer
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Prostate Cancer
Patricia Stewart
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Prostate Cancer
Last modified: July 22, 2021